EP3174987A4 - Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables - Google Patents
Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables Download PDFInfo
- Publication number
- EP3174987A4 EP3174987A4 EP15827888.7A EP15827888A EP3174987A4 EP 3174987 A4 EP3174987 A4 EP 3174987A4 EP 15827888 A EP15827888 A EP 15827888A EP 3174987 A4 EP3174987 A4 EP 3174987A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- reactions
- mrgprb2
- mrgprx2
- prevent
- cell based
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010067484 Adverse reaction Diseases 0.000 title 1
- 230000006838 adverse reaction Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 238000000423 cell based assay Methods 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Biodiversity & Conservation Biology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462032350P | 2014-08-01 | 2014-08-01 | |
PCT/US2015/043116 WO2016019246A1 (fr) | 2014-08-01 | 2015-07-31 | Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3174987A1 EP3174987A1 (fr) | 2017-06-07 |
EP3174987A4 true EP3174987A4 (fr) | 2018-02-21 |
EP3174987B1 EP3174987B1 (fr) | 2023-10-11 |
Family
ID=55218352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15827888.7A Active EP3174987B1 (fr) | 2014-08-01 | 2015-07-31 | Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables |
Country Status (8)
Country | Link |
---|---|
US (2) | US10696971B2 (fr) |
EP (1) | EP3174987B1 (fr) |
JP (2) | JP2017524382A (fr) |
CN (1) | CN107002087B (fr) |
AU (1) | AU2015296135A1 (fr) |
CA (1) | CA2957025A1 (fr) |
ES (1) | ES2961366T3 (fr) |
WO (1) | WO2016019246A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018075574A1 (fr) | 2016-10-18 | 2018-04-26 | Emergo Therapeutics, Inc. | Stabilisateurs de mastocytes pour le traitement d'états inflammatoires chroniques |
CA3067045A1 (fr) * | 2017-06-16 | 2018-12-20 | The Johns Hopkins University | Compositions et procedes pour traiter des affections mediees par les recepteurs couples aux proteines g |
CN107142325A (zh) * | 2017-06-28 | 2017-09-08 | 西安交通大学 | 一种用于药物类过敏反应敏感人群筛查的基因标志物及其应用 |
CN108398517A (zh) * | 2018-02-11 | 2018-08-14 | 湖南正清制药集团股份有限公司 | 一种筛查正清风痛宁制剂中潜在致敏组分的方法 |
US20220227859A1 (en) | 2019-05-16 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat type 2 inflammation or mast-cell dependent disease |
CN110240643B (zh) * | 2019-05-31 | 2021-05-28 | 西安交通大学 | 一种用于制备类过敏反应的双抗夹心试剂盒配对抗体的多肽及其应用 |
CN110229227B (zh) * | 2019-05-31 | 2021-05-28 | 西安交通大学 | 一种用于制备elisa鼠单克隆包被抗体和兔多克隆检测抗体的多肽及其应用 |
CN110204606B (zh) * | 2019-05-31 | 2021-04-20 | 西安交通大学 | 一种用于制备兔多克隆抗体的多肽及其应用 |
CN110229228B (zh) * | 2019-05-31 | 2021-05-28 | 西安交通大学 | 一种对类过敏反应特异性受体mrgprx2蛋白的具有免疫原性的多肽及其应用 |
CN110204607B (zh) * | 2019-05-31 | 2021-04-20 | 西安交通大学 | 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用 |
KR102494928B1 (ko) * | 2020-03-31 | 2023-02-03 | 재단법인 아산사회복지재단 | Mrgprx2를 이용한 즉시형 과민 반응 환자를 판별하는 방법 |
CN111500708A (zh) * | 2020-05-08 | 2020-08-07 | 中南大学湘雅医院 | 一种与麻醉药物过敏相关分子标记及其应用和检测试剂盒 |
WO2022073904A1 (fr) | 2020-10-06 | 2022-04-14 | Glaxosmithkline Intellectual Property Development Limited | Antagonistes de mrgx2 |
WO2023230322A1 (fr) * | 2022-05-27 | 2023-11-30 | Stealth Biotherapeutics Inc. | Adressage de réactions au site d'injection associées à l'administration de l'élamiprétide |
CN116814689B (zh) * | 2023-06-30 | 2024-04-05 | 海湃泰克(北京)生物医药科技有限公司 | 特异性表达hMRGPRX2的转基因小鼠的构建方法及其应用 |
CN116855503B (zh) * | 2023-08-30 | 2023-12-08 | 上海益诺思生物技术股份有限公司 | 过表达mrgprx2的稳转细胞株及其构建方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016159A1 (fr) * | 1999-08-27 | 2001-03-08 | Smithkline Beecham Corporation | Gpcr, ant |
US20050164288A1 (en) * | 2000-05-04 | 2005-07-28 | Anderson David J. | Pain signaling molecules |
EP1876239A1 (fr) * | 2005-04-28 | 2008-01-09 | Takeda Pharmaceutical Company Limited | Inhibiteur de degranulation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO2001011022A1 (fr) | 1999-08-05 | 2001-02-15 | Smithkline Beecham Corporation | Recepteur edg3 couple a la proteine g des souris |
JP2002355052A (ja) | 2000-07-07 | 2002-12-10 | Takeda Chem Ind Ltd | 新規g蛋白質共役型レセプター蛋白質およびそのdna |
EP1340979A3 (fr) * | 2002-02-27 | 2004-02-04 | Pfizer Limited | Récepteur neuropeptidique et son utilisation |
WO2005028667A1 (fr) | 2003-09-19 | 2005-03-31 | Riken | Recepteur couple a la proteine g pour le ciblage de medicament exprime dans des mastocytes humains et procede de criblage de ce recepteur |
JP2005304438A (ja) | 2004-04-26 | 2005-11-04 | Astellas Pharma Inc | 新規スクリーニング方法 |
WO2007055823A2 (fr) * | 2005-10-28 | 2007-05-18 | Multispan, Inc. | Lignees cellulaires et anticorps exprimant le gpcr |
JP2009060787A (ja) * | 2005-11-15 | 2009-03-26 | Gunma Univ | Rec168を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにRec168アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤 |
NZ586665A (en) | 2008-01-14 | 2011-12-22 | Probiodrug Ag | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE (Qpct) |
WO2010065085A2 (fr) | 2008-12-01 | 2010-06-10 | The Johns Hopkins University | Procédé et composition pour le traitement ou la prévention du prurit |
JP2012178985A (ja) | 2011-02-28 | 2012-09-20 | Univ Of Tokyo | 骨量増加剤のスクリーニング方法 |
ES2659184T3 (es) * | 2013-06-18 | 2018-03-14 | Bayer Pharma Aktiengesellschaft | Moduladores del receptor MRG |
-
2015
- 2015-07-31 EP EP15827888.7A patent/EP3174987B1/fr active Active
- 2015-07-31 CA CA2957025A patent/CA2957025A1/fr active Pending
- 2015-07-31 ES ES15827888T patent/ES2961366T3/es active Active
- 2015-07-31 CN CN201580053612.XA patent/CN107002087B/zh active Active
- 2015-07-31 WO PCT/US2015/043116 patent/WO2016019246A1/fr active Application Filing
- 2015-07-31 US US15/329,383 patent/US10696971B2/en active Active
- 2015-07-31 AU AU2015296135A patent/AU2015296135A1/en not_active Abandoned
- 2015-07-31 JP JP2017526479A patent/JP2017524382A/ja active Pending
-
2020
- 2020-06-05 US US16/894,363 patent/US20200370051A1/en not_active Abandoned
- 2020-06-08 JP JP2020099240A patent/JP2020141708A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016159A1 (fr) * | 1999-08-27 | 2001-03-08 | Smithkline Beecham Corporation | Gpcr, ant |
US20050164288A1 (en) * | 2000-05-04 | 2005-07-28 | Anderson David J. | Pain signaling molecules |
EP1876239A1 (fr) * | 2005-04-28 | 2008-01-09 | Takeda Pharmaceutical Company Limited | Inhibiteur de degranulation |
Non-Patent Citations (8)
Title |
---|
BENJAMIN D. MCNEIL ET AL: "Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions", NATURE, vol. 519, no. 7542, 12 March 2015 (2015-03-12), pages 237 - 241, XP055391597, ISSN: 0028-0836, DOI: 10.1038/nature14022 * |
DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Amino acid sequence of a human G-protein coupled receptor (Ant).", retrieved from EBI accession no. GSP:AAB67654 Database accession no. AAB67654 * |
DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Human TGR12 protein.", retrieved from EBI accession no. GSP:AEN62979 Database accession no. AEN62979 * |
DATABASE Geneseq [online] 20 September 2007 (2007-09-20), "Human Rec168 SEQ ID NO 1.", XP002776681, retrieved from EBI accession no. GSP:AGB13466 Database accession no. AGB13466 * |
OKAYAMA YOSHIMICHI ET AL: "Targeting human mast cells expressing g-protein-coupled receptors in allergic diseases", ALLERGOLOGY INTERNATIONAL, JAPANESE SOCIETY OF ALLERGOLOGY, JP, vol. 57, no. 3, 1 September 2008 (2008-09-01), pages 197 - 203, XP002496192, ISSN: 1323-8930, DOI: 10.2332/ALLERGOLINT.R-08-163 * |
SAKEEN W. KASHEM ET AL: "G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: Roles of Mas-related genes MrgX1 and MrgX2", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 668, no. 1-2, 1 October 2011 (2011-10-01), NL, pages 299 - 304, XP055434889, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2011.06.027 * |
SUBRAMANIAN HARIHARAN ET AL: "Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 138, no. 3, 20 July 2016 (2016-07-20), pages 700 - 710, XP029712341, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2016.04.051 * |
TATEMOTO K ET AL: "Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 349, no. 4, 3 November 2006 (2006-11-03), pages 1322 - 1328, XP024924577, ISSN: 0006-291X, [retrieved on 20061103], DOI: 10.1016/J.BBRC.2006.08.177 * |
Also Published As
Publication number | Publication date |
---|---|
JP2020141708A (ja) | 2020-09-10 |
US20200370051A1 (en) | 2020-11-26 |
AU2015296135A1 (en) | 2017-02-16 |
WO2016019246A1 (fr) | 2016-02-04 |
CN107002087A (zh) | 2017-08-01 |
JP2017524382A (ja) | 2017-08-31 |
CA2957025A1 (fr) | 2016-02-04 |
ES2961366T3 (es) | 2024-03-11 |
EP3174987B1 (fr) | 2023-10-11 |
US20170204419A1 (en) | 2017-07-20 |
CN107002087B (zh) | 2021-09-28 |
EP3174987A1 (fr) | 2017-06-07 |
US10696971B2 (en) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3174987A4 (fr) | Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables | |
IL246080A0 (en) | Saliva bio-sensors and biofuel cells | |
EP3116801A4 (fr) | Réceptacles à double détection | |
EP3210010A4 (fr) | Dispositifs microfluidiques numériques avec capteurs électrochimiques intégrés | |
EP3040025A4 (fr) | Système de détection d'analyte | |
EP3114716A4 (fr) | Cellules de batterie et agencements | |
EP3134719A4 (fr) | Capteur de particules avec discrimination d'agents perturbateurs | |
EP3104151A4 (fr) | Capteur de force et structure utilisée en son sein | |
EP3211392A4 (fr) | Capteur de détection d'état | |
EP3165933A4 (fr) | Dispositif de détermination d'état de batterie | |
EP3193387A4 (fr) | Ensemble d'interconnexion de cellule de batterie et de détection de tension, et module de batterie | |
EP3093907A4 (fr) | Élément de batterie comportant un trou | |
EP3171428A4 (fr) | Batterie équipée d'une borne usb | |
EP3228370A4 (fr) | Système de puzzle fonctionnant en concordance avec un dispositif externe | |
EP3107142A4 (fr) | Cellule de batterie à structure renfoncée et asymétrique | |
EP3116396A4 (fr) | Système de détection électrochimique | |
EP3134724B8 (fr) | Cellule électrochimique | |
EP3109922A4 (fr) | Ensemble de détection de tension et d'interconnexion de cellules de batterie, et module de batterie | |
EP3191578A4 (fr) | Cellules exprimant l'apolipoprotéine e et leurs utilisations | |
EP3167281A4 (fr) | Puce de capteur électrochimique | |
EP3259066A4 (fr) | Dispositif, plateforme et essai d'évaluation de cellules | |
EP3172560A4 (fr) | Capteurs électrochimiques, encapsulation et procédés associés | |
EP3212821A4 (fr) | Module de bioréacteur électrochimique amélioré et son utilisation | |
EP3155408A4 (fr) | Capteurs et électrodes à solide | |
EP3125352A4 (fr) | Électrolyte et dispositif électrochimique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
17P | Request for examination filed |
Effective date: 20170210 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180124 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/7088 20060101ALI20180115BHEP Ipc: C07K 14/705 20060101ALI20180115BHEP Ipc: C12N 15/85 20060101ALI20180115BHEP Ipc: G01N 35/00 20060101ALI20180115BHEP Ipc: C12N 15/63 20060101AFI20180115BHEP Ipc: A61P 37/08 20060101ALI20180115BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190328 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602015086079 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12N0015630000 Ipc: A01K0067027000 Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12N0015630000 Ipc: A01K0067027000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/08 20060101ALI20230310BHEP Ipc: C07K 14/705 20060101ALI20230310BHEP Ipc: G01N 33/50 20060101ALI20230310BHEP Ipc: C12N 15/113 20100101ALI20230310BHEP Ipc: C07K 14/72 20060101ALI20230310BHEP Ipc: A61K 31/7105 20060101ALI20230310BHEP Ipc: A01K 67/027 20060101AFI20230310BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230503 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015086079 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20231011 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2961366 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240311 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1619266 Country of ref document: AT Kind code of ref document: T Effective date: 20231011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231011 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240211 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240112 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240111 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231011 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240212 |